Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

昭衍
JOINN

JOINN LABORATORIES (CHINA) CO., LTD.
北京昭衍新藥研究中心股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6127)

ESTIMATED RESULTS FOR THE HALF YEAR OF 2026

This announcement is made by JOINN Laboratories (China) Co., Ltd. (the "**Company**") pursuant to the Inside Information Provisions (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Listing Rules**")) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Hong Kong Listing Rules.

I. ESTIMATED RESULTS FOR THE HALF YEAR OF 2026

(I) Period of estimated results

From 1 January 2026 to 30 June 2026.

(II) Estimated results

The board of directors (the "**Board**") of the Company wishes to inform shareholders and potential investors of the Company that, based on the preliminary review and assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 (the "**First Half of 2026**") prepared pursuant to China Accounting Standards for Business Enterprises:

1. It is expected that the revenue for the First Half of 2026 will be approximately RMB668,628,100 to RMB739,010,000, and will increase approximately RMB52,900 to RMB70,434,800 as compared with the data for the corresponding period of last year, representing a period-on-period increase of approximately 0% to 10.5%.

2. It is expected that the net profit attributable to the shareholders of the Company for the First Half of 2026 will be approximately RMB600,125,700 to RMB900,188,600, and will increase approximately RMB539,193,300 to RMB839,256,200 as compared with the data for the corresponding period of last year, representing a period-on-period increase of approximately 884.9% to 1,377.4%.

3. It is expected that the net profit attributable to the shareholders of the Company after deducting non-recurring gains and losses for the First Half of 2026 will be approximately RMB561,142,800 to RMB841,714,200, and will increase approximately RMB538,090,600 to RMB818,662,000 as compared with the data for the corresponding period of last year, representing a period-on-period increase of approximately 2,334.2% to 3,551.3%. In particular:

   3.1 Net profit from changes in fair value of biological assets will be approximately RMB702,765,300 to RMB776,740,600.

   3.2 Net profit from laboratory services and others business will be approximately RMB-141,622,500 to RMB64,973,600.

   Note:

   Net profit from laboratory services and others business: the net profit attributable to the shareholders of the Company after deducting non-recurring gains and losses after excluding the effects of gains or losses from changes in fair value of biological assets.

(III) The estimated results have not been audited by certified public accountants.

II. RESULTS FOR THE CORRESPONDING PERIOD OF THE PREVIOUS YEAR

1. Revenue of the Company: RMB668,575,200.

2. Net profit attributable to the shareholders of the Company: RMB60,932,400.

3. Net profit attributable to the shareholders of the Company after deducting non-recurring gains and losses: RMB23,052,200. In particular:

   3.1 Net profit from changes in fair value of biological assets: RMB87,854,100

   3.2 Net profit from laboratory services and others business: RMB-64,801,900

4. Earnings per share: RMB0.08.

III. MAIN REASONS FOR THE CHANGES IN RESULTS DURING THE CURRENT PERIOD

(I) During the reporting period, the increase in the market price of biological assets, coupled with their own organic growth and appreciation, drove positive changes in their fair value, making a positive contribution to the Company's results.

(II) During the reporting period, the Company's laboratories continued to maintain a stable and sound operating status. Although the industry as a whole has recovered, due to the lagging effects of the fierce competition in the industry in the early stage, the revenue only achieved a slight increase in this period, and the gross profit level still needs to be restored.

IV. RISK WARNING

There are no material uncertainties affecting the accuracy of the estimated results.

V. OTHER EXPLANATION

As the Company is still in the process of preparing and finalizing its interim results announcement of 2026, the information contained in this announcement is only based on the preliminary assessment by the Company on the unaudited consolidated management accounts of the Group for the First Half of 2026 based on the information currently available, which have not been audited by the Company's auditors. Therefore, the actual results of the Group for the First Half of 2026 may be different from those disclosed in this announcement. Shareholders and potential investors of the Company should read the interim results announcement of 2026 of the Group carefully, which is expected to be published by the end of August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
JOINN Laboratories (China) Co., Ltd.
Feng Yuxia
Chairperson

Hong Kong, 14 July 2026

As at the date of this announcement, the Board comprises Ms. Feng Yuxia as the Chairperson and executive Director, Mr. Gao Dapeng, Ms. Sun Yunxia, Mr. Gu Jingliang and Ms. Luo Xi as executive Directors, Mr. Zhou Fengyuan as a non-executive Director, Mr. Zhang Fan, Mr. Yang Changyun, Mr. Yang Fuquan and Mr. Ying Fangtian as independent non-executive Directors, and Ms. Li Ye as an employee Director.